Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples